Search results for "Haematologic"

showing 10 items of 17 documents

Reflections on the unexpected laboratory finding of hemorheological alterations observed in some haematological disorders

2021

Hyperviscosity syndrome is a clinical condition characterized by the slowing of blood flow through the vessels and it may be associated with several diseases. The nosographic classification of primary hyperviscosity conditions (Wells classification 1970) divided the primary hyperviscosity syndromes in polycythaemic, sclerocytemic and sieric. Recent and personal laboratory observations have highlighted an unexpected behaviour of the erythrocyte deformability observed in some haematological disorders such as polycythemia vera, multiple myeloma and monoclonal gammopathy of undetermined significance. The interest of this observation depends on the fact that up to now, according to the Wells cla…

0301 basic medicinemedicine.medical_specialtyLaboratory findingHyperviscosityMonoclonal gammopathy of undetermined significance030204 cardiovascular system & hematologyBiochemistryHyperviscosity syndromes03 medical and health sciences0302 clinical medicinePolycythemia veraMultiple myelomaErythrocyte DeformabilityHyperviscosity syndromemedicineAnimalsHumansIntensive care medicinePolycythemia VeraMultiple myelomabusiness.industryModels CardiovascularCell Biologymedicine.diseaseBlood Viscosity030104 developmental biologyAbnormalityCardiology and Cardiovascular MedicinebusinessMonoclonal gammopathy of undetermined significanceHaematological disorders
researchProduct

Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000–14 (CONCO…

2022

BACKGROUND Leukaemias comprise a heterogenous group of haematological malignancies. In CONCORD-3, we analysed data for children (aged 0-14 years) and adults (aged 15-99 years) diagnosed with a haematological malignancy during 2000-14 in 61 countries. Here, we aimed to examine worldwide trends in survival from leukaemia, by age and morphology, in young patients (aged 0-24 years). METHODS We analysed data from 258 population-based cancer registries in 61 countries participating in CONCORD-3 that submitted data on patients diagnosed with leukaemia. We grouped patients by age as children (0-14 years), adolescents (15-19 years), and young adults (20-24 years). We categorised leukaemia subtypes a…

AdolescentAustralia610 Medicine & healthlymphomaSettore MED/42 - Igiene Generale E ApplicatasurvivalUnited StatesEuropeLeukemia Myeloid AcuteYoung Adultchildrenpopulation-based/cancer registry360 Social problems & social servicessurvival leukemia cancer registryHematologic NeoplasmsleukaemiaPediatrics Perinatology and Child HealthDevelopmental and Educational PsychologycancerHumansRegistrieshaematological malignancy610 Medicine & healthChild360 Social problems & social services
researchProduct

Ultrasonography-guided central venous catheterisation in haematological patients with severe thrombocytopenia

2012

BACKGROUND: Cannulation of the internal jugular vein (CVC) is a blind surface landmark-guided technique that could be potentially dangerous in patients with very low platelet counts. In such patients, ultrasonography (US)-guided CVC may be a valid approach. There is a lack of published data on the efficacy and safety of urgent US-guided CVC performed in haematological patients with severe thrombocytopenia. MATERIALS AND METHODS: We retrospectively studied the safety of urgent CVC procedures in haematological patients including those with severe thrombocytopenia (platelet count <30×10(9)/L). From January 1999 to June 2009, 431 CVC insertional procedures in 431 consecutive patients were evalu…

AdultAged 80 and overMaleCatheterization Central VenousAdolescentOriginal ArticlesMiddle AgedSeverity of Illness IndexThrombocytopeniaSettore MED/15 - Malattie Del SangueSettore MED/18 - Chirurgia Generalecentral venous catheterisation ultrasound Seldinger technique low platelet count haematological malignancyHumansFemaleAgedRetrospective StudiesUltrasonography
researchProduct

Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

2021

AbstractThere is evidence of reduced SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies. We hypothesized that tumor and treatment-related immunosuppression can be depicted in peripheral blood, and that immune profiling prior to vaccination can help predict immunogenicity. We performed a comprehensive immunological characterization of 83 hematological patients before vaccination and measured IgM, IgG, and IgA antibody response to four viral antigens at day +7 after second-dose COVID-19 vaccination using multidimensional and computational flow cytometry. Health care practitioners of similar age were the control group (n = 102). Forty-four out of 59 immune cell types …

AdultAged 80 and overMaleHaematological cancerCOVID-19 VaccinesSARS-CoV-2COVID-19Vaccine EfficacyNeoplasms. Tumors. Oncology. Including cancer and carcinogenslymphomaHematologyMiddle Agedhematologic malignancieArticleImmunocompromised HostmyelomaOncologyHematologic NeoplasmsHumansTumour immunologyFemaleSars-cov-BiomarkersRC254-282AgedBlood Cancer Journal
researchProduct

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem‐cell transplantation

2011

Antifungal prophylaxis for allogeneic haematopoietic stem-cell transplant (alloHCT) recipients should prevent invasive mould and yeast infections (IFIs) and be well tolerated. This prospective, randomized, open-label, multicentre study compared the efficacy and safety of voriconazole (234 patients) versus itraconazole (255 patients) in alloHCT recipients. The primary composite endpoint, success of prophylaxis, incorporated ability to tolerate study drug for ≥100 d (with ≤14 d interruption) with survival to day 180 without proven/probable IFI. Success of prophylaxis was significantly higher with voriconazole than itraconazole (48·7% vs. 33·2%, P 10%) treatment-related adverse events were vom…

AdultMalemedicine.medical_specialtyAntifungal AgentsAdolescentItraconazoleazolesstem-cell transplantPharmacologyBiologyAspergillosisGastroenterologyYoung AdultInternal medicineAmphotericin BmedicineHumansTransplantation Homologousyeast infectionsProspective StudiesChildAdverse effectAgedVoriconazoleHaematological MalignancyHematopoietic Stem Cell TransplantationHematologyMiddle AgedTriazolesmedicine.diseaseinvasive fungal diseaseTransplantationPyrimidinesMycosesmould infectionsFemaleVoriconazoleLiver functionItraconazoleFluconazolemedicine.drugBritish Journal of Haematology
researchProduct

742 EFFICACY AND SAFETY OF ENTECAVIR (ETV) PROPHYLAXIS IN INACTIVE HBV CARRIERS WHO UNDERWENT CHEMOTHERAPY FOR SOLID OR HAEMATOLOGICAL CANCER: INTERI…

2013

seroconversion rate at 48 weeks were 40.7% and 37% in PEG-IFN a-2a group, respectively, which are both higher than those in ETV group (16.7% and 13.3%, P all 0.05). The mean qHBsAg level in PEG-IFN a-2a group declined over time during treatment. The qHBsAg level at 48 weeks was significantly lower than that in ETV group ((2866.0±2580.4) vs (4335.8±2650.0) IU/mL, P = 0.027). A greater HBsAg decline was observed in HBeAg seroconverters compared with nonseroconverters. The decline from baseline was significantly different between seroconverters and non-seroconverters especially at 36 weeks ((1763.4±3116.2) vs (1333.5±2483.4) IU/mL, P = 0.036), and 48 weeks (1979.6±2897.1) vs (1631.8±2395.8) IU…

Chemotherapymedicine.medical_specialtyHBsAgHepatologybusiness.industrymedicine.medical_treatmentEntecavirInterim analysisGastroenterologySurgeryHBeAgInternal medicineHaematological cancerMedicineSeroconversionbusinessmedicine.drugCohort studyJournal of Hepatology
researchProduct

Drug-related cardiotoxicity for the treatment of haematological malignancies in elderly.

2010

Several publications have focused on the cardiotoxicity of specific classes of haematological therapeutic agents such as antracyclines and cyclofosfamide. Cardiotoxicity of cancer chemotherapeutics is a problem for patients of all ages, but it increases with age. Toxicity can also be developed months after the last chemotherapy dose, and late reactions can be seen years later when they present new-onset cardiomyopathy. No data are available about the cardiotoxicity of non-chemotherapy agents currently used as preferred therapy for haematological malignancy in elderly. In this review we have provided a summary of the cardiovascular toxic effects produced by different drugs and therapeutic ag…

Drugmedicine.medical_specialtyHeart diseaseHeart Diseasesmedicine.medical_treatmentmedia_common.quotation_subjectCardiomyopathyAntineoplastic AgentsPharmacologyCardiotoxinsDrug Delivery SystemsDrug DiscoverymedicineAnimalsHumansIntensive care medicinedrug cardiotoxicity haematological malignanciesmedia_commonAgedPharmacologyCardiotoxicityChemotherapybusiness.industryAge FactorsCancerImatinibmedicine.diseaseHematologic NeoplasmsRituximabbusinessmedicine.drugCurrent pharmaceutical design
researchProduct

Whole-Body MRI and 18F-FDG-PET-CT for Lymphoma Staging: Comparison of Patient Experience

2015

Aims and objectives Methods and materials Results Conclusion Personal information References

MRI Lymphomagenetic structuresLymphomaNuclear medicinePET-CTSettore MED/36 - Diagnostica Per Immagini E RadioterapiaDiagnostic procedureLymph nodesHaematologic diseasesHaematologicMR-Diffusion/Perfusion
researchProduct

Sudden sensorineural hearing loss: is there a relationship between routine haematological parameters and audiogram shapes?

2016

Objective: To investigate the relationship between haematological routine parameters and audiogram shapes in patients affected by sudden sensorineural hearing loss (SSNHL). Design: A retrospective study. All patients were divided into four groups according to the audiometric curve and mean values of haematological parameters (haemoglobin, white blood cell, neutrophils and lymphocytes relative count, platelet count, haematocrit, prothrombin time, activated partial thromboplastin time, fibrinogen and neutrophil-to-lymphocite ratio) of each group were statistically compared. The prognostic role of blood profile and coagulation test was also examined. Study sample: A cohort of 183 SSNHL patient…

MaleTime FactorsNeutrophilshaematological parameterAudiologyLanguage and LinguisticsHemoglobinsLeukocyte Count0302 clinical medicineHearingLymphocytes030223 otorhinolaryngologyHematologic Testsmedicine.diagnostic_testComplete blood countAudiogramSudden sensorineural hearing lossMiddle AgedSettore MED/32 - AudiologiaTreatment OutcomeSettore MED/31 - Otorinolaringoiatriamedicine.anatomical_structureHematocrit030220 oncology & carcinogenesisCohortAudiometry Pure-ToneFemalePartial Thromboplastin TimeSteroidsmedicine.symptomPartial thromboplastin timeAdultBlood PlateletsLinguistics and Languagemedicine.medical_specialtyHearing lossHearing Loss Sensorineural03 medical and health sciencesSpeech and HearingAudiogram shapePredictive Value of TestsWhite blood cellmedicineHumansBlood CoagulationRetrospective StudiesProthrombin timePlatelet Countbusiness.industryFibrinogenAuditory ThresholdRetrospective cohort studyRecovery of FunctionHearing Loss Suddenaudiogram shape; haematological parameters; Sudden sensorineural hearing lossProthrombin TimebusinessBiomarkersInternational Journal of Audiology
researchProduct

Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project

2010

AbstractChanging definitions and classifications of hematologic malignancies (HMs) complicate incidence comparisons. HAEMACARE classified HMs into groupings consistent with the latest World Health Organization classification and useful for epidemiologic and public health purposes. We present crude, age-specific and age-standardized incidence rates for European HMs according to these groupings, estimated from 66 371 lymphoid malignancies (LMs) and 21 796 myeloid malignancies (MMs) registered in 2000-2002 by 44 European cancer registries, grouped into 5 regions. Age-standardized incidence rates were 24.5 (per 100 000) for LMs and 7.55 for MMs. The commonest LMs were plasma cell neoplasms (4.6…

Malemedicine.medical_specialtyPathologyChildhood leukemiaHematologic malignant; Europe; morphologic subtype; international comparison; population-based cancer registry.ImmunologyPopulationUNITED-STATESALCOHOLBiochemistryNOMyelodysplastic–myeloproliferative diseasesInternal medicineEpidemiologymorphologymedicineLYMPHOMAHumansEPIDEMIOLOGYRegistriesEXPOSUREeducationRISKeducation.field_of_studyTOBACCOhaematologic malignanciesbusiness.industryIncidence (epidemiology)IncidenceleukemiaMyeloid leukemiaCell BiologyHematologyHematologic malignancies; morphology; Europe.Plasma cell neoplasmmedicine.diseaseMyelodysplastic-Myeloproliferative DiseasesLymphomaEuropeCANCER INCIDENCEHematologic Neoplasmscancer incidence tobacco alcohol epidemiology leukemia risk exposureCHILDHOOD LEUKEMIAHematologic malignanciesFemalebusiness
researchProduct